Luther King Capital Management (LKCM)
IMUC

Luther King Capital Management (LKCM)’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Luther King Capital Management (LKCM)’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-250
Closed -$7K – 525
2016
Q3 		$7K Hold
250
– – ﹤0.01% 489
2016
Q2 		$7K Hold
250
– – ﹤0.01% 512
2016
Q1 		$7K Hold
250
– – ﹤0.01% 506
2015
Q4 		$4K Hold
250
– – ﹤0.01% 517
2015
Q3 		$4K Hold
250
– – ﹤0.01% 529
2015
Q2 		$7K Hold
250
– – ﹤0.01% 544
2015
Q1 		$7K Hold
250
– – ﹤0.01% 537
2014
Q4 		$7K Hold
250
– – ﹤0.01% 551
2014
Q3 		$9K Hold
250
– – ﹤0.01% 556
2014
Q2 		$11K Hold
250
– – ﹤0.01% 546
2014
Q1 		$12K Hold
250
– – ﹤0.01% 535
2013
Q4 		$9K Hold
250
– – ﹤0.01% 512
2013
Q3 		$26K Hold
250
– – ﹤0.01% 669
2013
Q2 		$19K Buy
+250
New +$23.9K ﹤0.01% 672

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Luther King Capital Management (LKCM)'s IMUC Position: Q4 2016 in Review

Luther King Capital Management (LKCM) sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2016, closing a stake of 250 shares — an estimated $7K sold.

Luther King Capital Management (LKCM) first reported a position in IMUC in Q2 2013 and held it in 14 quarters. The position peaked at $26K in Q3 2013. 16 funds tracked by Wall St. Rank hold IMUC as of Q4 2016.

  • Luther King Capital Management (LKCM) reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2016 after selling out during the quarter.
  • Luther King Capital Management (LKCM) sold 250 ImmunoCellular Therapeutics, Ltd. shares in Q4 2016, an estimated $7K.
  • Luther King Capital Management (LKCM) first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 14 quarters.
  • Luther King Capital Management (LKCM)'s ImmunoCellular Therapeutics, Ltd. position peaked at $26K in Q3 2013.
  • 16 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2016.

Based on Luther King Capital Management (LKCM)'s 13F filing for Q4 2016, filed 10 Feb 2017.